Department of Surgery, University of British Columbia, and the BC Cancer Agency, Department of Cancer Surveillance & Outcomes, Surgical Oncology Network, 2775 Laurel Street, Vancouver, BC, Canada.
A pancreaticoduodenectomy is the reference treatment for a resectable pancreatic head ductal adenocarcinoma. The probability of 5-year survival in patients undergoing such treatment is 5-25% and is associated with relatively high peri-operative morbidity and mortality. The objective of the present study was to evaluate risk factors predictive of outcome for patients undergoing a pancreaticoduodenectomy for a pancreatic adenocarcinoma.
This retrospective analysis incorporated data from the Vancouver General Hospital and the British Columbia Cancer Agency (BCCA) from 1999-2007.
The 5-year survival of 100 patients was 12% with a median survival of 16.5 months. Ninety-day mortality was 7%. Predictors of 90-day mortality included age = 80 years (P
Notes
Cites: J Natl Cancer Inst Monogr. 2001;(28):5-911158200
Cites: N Engl J Med. 2011 Jun 2;364(22):2128-3721631325